Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.
GlobalData on MSN20h
Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatmentEntrada Therapeutics has secured authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and ...
Decker was given the 2025 MDA Legacy Award, recognizing his efforts to advance gene therapy, scientific research, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback